LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it plans to move CB-183,315, being studied for the treatment of a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD, into late-stage trials. Positive results from a Phase 2 trial for CB-183,315 were announced earlier this year in June, and data from that study were presented earlier this month at the 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago. Cubist expects to initiate Phase 3 trials in the first half of 2012.
